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We have cloned and sequenced anovel cDNA (RPR7) encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP). RPR7 
was identified by PCR of rat pituitary cDNA, and full-length clones were isolated from a rat olfactory bulb cDNA library. When expressed in 
COS cells, RPR7 was functionally coupled to increases in intracellular cyclic adenosine monophosphate (CAMP) in response to stimulation by 
PACAP-38, PACAP-27, vasoactive intestinal peptide (VIP) and peptide histidine isoleucine (PHI). The order of potency of these ligands was 
PACAP- - PACAP- > VIP > PHI, suggesting that the receptor corresponds to the pharmacologically character&d PACAP Type I receptor. 
Pituitary adenylate cyclase activating polypeptide (PACAP); G protein-linked receptor; Vasoactive intestinal peptide; Rat pituitary; Rat olfactory 
bulb: cDNA cloning 
1. INTRODUCTION 
Pituitary adenylate cyclase activating polypeptide 
(PACAP) was identified and purified on the basis of its 
ability to stimulate the accumulation of CAMP in rat 
pituitary cells in culture. Two forms of the peptide have 
been isolated from the hypothalamus, one of 38 amino 
acids (PACAP-38) [I] and a C-terminally truncated 
form of 27 amino acids (PACAP-27) [2]. PACAP is 
closely related to VIP (68% sequence homology within 
the N-terminal 28 residues) and more distantly related 
to glucagon, glucagon-like peptide I (GLP), PHI, se- 
cretin and growth hormone releasing hormone 
(GHRH). All of these peptides are thought to exert their 
actions through G-protein linked membrane receptors 
coupled to adenylyl cyclase. Recently, the receptors for 
VIP [3,4], glucagon [5-71, GLP [8], GHRH [9-111 and 
secretin [12] have been cloned. Together with receptors 
for calcitonin [13,14] and parathyroid hormone (PTH) 
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[15-171 they form a protein family distinct from other 
G protein-linked receptors. 
PACAP- and PACAP- have been shown to bind 
with high affinity to VIP receptors in a variety of tissues. 
However, specific PACAP receptors (‘Type I PACAP 
receptors’) to which VIP can bind with only modest 
affinity have also been described in brain and other 
tissues (for review see [18]). We report here the cloning 
and expression of a specific, adenylyl cyclase-linked 
Type I PACAP receptor (RPR7) from rat brain. RPR7 
was identified by PCR of rat pituitary cDNA using 
degenerate oligonucleotide primers corresponding to 
the third and seventh transmembrane domains of the 
secretin family of G protein-linked receptors. Full- 
length cDNAs were isolated from an olfactory bulb 
cDNA library. 
2. EXPERIMENTAL 
2.1. Cloning and sequence analysis of rat PACAP receptor 
Anterior pituitary glands from male rats (Cob Wistar, 250 g) were 
removed and total RNA was isolated by the method of Chomczynski 
and Sacchi [19]. Single-stranded cDNA synthesis and PCR were car- 
ried out using a commercial kit (Perkin Elmer Cetus). 1 pg RNA was 
annealed with 2.5 PM random hexanucleotide primers by heating to 
95°C for 15 min, then rapidly cooling to 4°C. Single-stranded cDNA 
was synthesised by incubating the oligonucleotide-RNA solution at 
42°C for 15 min in 20~1 10 mM Tris-HCl, pH 8.3, containing SO mM 
KCl, 5 mM MgCl,, 1 mM each dNTP, 20 U RNase inhibitor and 50 
U reverse transcriptase. The reaction was terminated by heating to 
99°C for 5 min. PCR was performed using a pair of degenerate 32-mer 
oligonucleotide primers (Fig. 1), corresponding to conserved regions 
in the third and seventh transmembrane domains of the rat secretin 
[12], pig calcitonin [14] and opossum PTH [16] receptors. Reactions 
(100 ,ul) contained 30 pmol of each primer, 20 ~1 reverse transcriptase 
reaction and 2.5 U Amplitaq DNA polymerase in 50 mM KCl, 10 mM 
Tris-HCl, pH 8.3 and 2 mM MgCIZ. 5 cycles of PCR (60 s denaturation 
Volume 329, number 1,2 FEBSLETTERS August 1993 
at 94”C, 60 s annealing at 45*C, 60 s extension at 60°C) were followed 
by a further 40 cycles (60 s denaturation at 94”C, 60 s+6 s per cycle 
annealing and extension at 6O“C) followed by 7 min at 60°C. PCR 
products were precipitated with ammonium acetate and ethanol, after 
which one half of each reaction was run on a 1% agarose gel. Five 
bands ranging in size from 500 to 900 bp were excised from the gel and 
purified using the Sephaglas BandPrep kit (Pharmacia), and one quar- 
ter was used for a further round of PCR (5 cycles of 60 s denaturation 
at 94”C, 60 s annealing at 47”C, 60 s extension at 60°C followed by 
a further 40 cycles of 60 s denaturation at 94’C, 60 s+6 s per cycle 
annealing and extension at 60°C followed by 7 min at 60°C. PCR 
products were ethanol precipitated, digested with BarnHI and EcoRI, 
separated on a 1% agarose_TAE gel, purified using the Sephaglas 
BandPrep kit (Pharmacia), ligated into pBlue~~pt (Strata~ne) and 
used to transform competent E. cob DS941. Clones with inserts of the 
expected siie were sequenced on both strands (Sequenase 2.0 kit; 
USB). 
One of the clones isolated, RPR7, was used to screen a commercial 
cDNA library in the AZap II vector prepared from rat olfactory bulb 
(Stratagene). Screening and plaque purification were performed using 
standard methods [20]. Positive clones were excised with ExAssist 
helper phage (Stratagene) and re-circularised to generate subclones in 
the pBluescript SK- vector prior to sequencing on both strands. For 
expression in transfected COS cells, the insert from the full-length 
clone (RPR719.1) was excised as an EcoRI fragment and ligated into 
the EcoRI site of the eukaryotic expression vector, pcDNA-1 (Invitro- 
gen). 
Total RNA was isolated from tissues using the guanidinium thiocy- 
anate/caesium chloride method [Zl]. Approximately 20 fig of each 
RNA was separated by electrophoresis on denaturing 1% agarosel 
formaldehyde gels, transferred to a nitrocellulose membrane 
(Hybond-C, Amersham) and baked for 2 h at 80°C. The membrane 
was then hybrid&d with the insert from RPR7 that had been labelled 
with [32P]dCTP using random hexanucleotide primers (Pharmacia) 
and the Klenow fragment of E. coli DNA polymerase. Hybridisation 
was performed overnight in 50% formamide, 25 mM KPQI, pH 7.4, 
5 x SSC (1 x SSC = 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 
5 x Denhardt’s olution, 50 &ml salmon sperm DNA at 45°C. The 
membranes were subsequently washed twice for 20 min in 2 x SSCl 
0.1% SDS at 5O”C, then twice more in 0.5 x SScIO.I% SDS at 50-C, 
and exposed to Fuji RX film. 
2.3. Cell culture and tramfection 
COS 7 cells (gift of Dr. Janet Allen) were grown in DMEM supple- 
mented with 10% new-born calf serum and 100 U/ml each of penicillin 
and streptomycin, in a humidified atmosphere of 95% air/ 5% CO, at 
a constant temperature of 37’C, and were passaged every 3-4 days. 
Cells for transfection were trypsinised the day before the experiment 
and plated at a density of approximately 40-5096 confluency in 75 cm’ 
flasks. 
For transfeetion, cells were washed twice with OptiMEM (Gibco) 
supplemented with 100 U/ml each of streptomycin and penicillin at 
37OC before exposure to transfecting medium for 4 h. The transfecting 
medium consisted of ~tiME~~nicilli~s~eptomycin, 400 @ml 
DEAE dextran (Promega), 1M) ,uM chlor~uine phosphate (Sigma) 
and 10-20 pg plasmid per flask. This was replaced with 10% DMSO 
in PBS for 2 min, then DMEM~% UltraSer G/~~~lli~streptomy- 
tin. Cells were grown for 24 h, then trypsinised and re-plated. Cells 
were harvested 48 h later. 
2.4. CAMP measurement 
For screening purposes, cells transfected with RPR7/9.1 were 
seeded onto 12-well tissue culture dishes, and for dose-response xper- 
iments, onto 24-well dishes. Prior to incubation with peptides, the 
cultures were washed with DMEM containing 0.25% BSA, and pre- 
incubated at 37°C for 30 min in the presence of 0.5 mM isobutyl 
methylxanthine. Peptides were directly added at concentrations indi- 
100 
cated in the figure legends, and incubated at 37°C for 15-30 min. The 
reaction was stopped by adding ice-cold 0.1 M HCl, and the cells 
homogenised by trituration. The levels of CAMP in the acidic extracts 
were measured by radioimmunoassay using antiserum cAB4 (courtesy 
of K.J. Catt, NICHD, NIH, Bethesda, MD) [22]. 
3. RESULTS 
3.1. Cloning and analysis of receptor cDNA clones 
The cloning of the calcitonin, secretin, and PTH re- 
ceptors, and their recognition as a new sub-class of 
peptide receptors, has provided a st~ctural basis for the 
cloning of other members of the secretin receptor fam- 
ily. Our strategy for the identification of new family 
members was based on the exceptionally high degree of 
sequence conservation found in the 3rd and 7th trans- 
membrane regions of these proteins. We designed de- 
generate oligonucleotide primers encoding portions of 
these sequences (Fig. l), and used them to amplify rat 
anterior pituitary cDNA. Several classes of PCR prod- 
uct were obtained, cloned into pBluescript, and the 
DNA sequence of several of the clones determined. The 
most abundant clone (7117 clones sequenced: designated 
RPR7) was very similar in sequence to the VIP receptor 
[3,4], but distinct from all the known members of the 
family. 
Northern blot analysis using RPR7 as a hybridisation 
probe (Fig. 2) revealed a transcript of approximately 9.5 
kb expressed in the pituitary and regions of the brain, 
with the highest levels being observed in the olfactory 
bulb. Accordingly, we screened a rat olfactory bulb 
cDNA library with probes for RPR7, and isolated a 
large number ( - 80 from a total of 800,000) of positive 
clones. Four independent positive clones were char- 
acterised by restriction mapping and partial sequencing. 
The 5’ termini of all four clones were identical and each 
algo2 3‘” A&;: ev; CCI =A, ;a, CA1 CO1 FAX $x .PG AC Octaves 
Fig. 1. Sequences of degenerate oligonucleotide primers used for PCR. 
Oligos 1 and 2 corresponded to conserved regions in the third and 
seventh transmembrane domains, respectively, of the secretin receptor 
family. Sequences containing restriction sites (EcoRI and BarnHI, 
respectively) were added to the 5’ ends of Oligo 1 and Oligo 2. Se- 
quences of the two oligonucleotides are shown, aligned with the corre- 
sponding amino acid sequences in the rat secretin, pig calcitonin and 
opossum PTH receptors. 
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contained sequences corresponding to RPR7. The com- 
plete sequence of one clone (designated RPR7/9.1) was 
determined: it consisted of 2,468 bp that contained an 
open reading frame encoding a protein of 495 amino 
acids with a predicted molecular weight of 56,000 kDA 
(Fig. 3A). A hydropathy plot indicated that RPR7/9.1 
encoded a protein with seven hydrophobic, putative 
membrane-spanning domains (Fig. 3B). 
Comparison with other members of the secretin fam- 
ily (Fig. 4A) revealed that RPR7/9.1 is related to the 
calcitonin (31% amino acid identity), PTH (37%), glu- 
cagon (38%), GLP (37%), GHRH (41%) and secretin 
(47%) receptors, with greatest similarity being found 
with the rat VIP receptor (51%). The highest sequence 
identity is found in the putative transmembrane r gions. 
The sequence of the amino-terminal extracellular do- 
mains are highly divergent, with the exception of spe- 
cific amino acid residues. In particular, there are six 
cysteine residues that are completely conserved between 
the RPR7/9.1, VIP and GHRH receptors and are prob- 
ably important for maintaining tertiary structure of the 
extracellular ligand binding domain. The carboxy-ter- 
minal cytoplasmic ends of each receptor are also highly 
divergent. 
Examination of the amino acid sequence of RPR7/9.1 
indicates a hydrophobic signal sequence at its amino- 
terminal end, with a predicted signal cleavage site be- 
tween Alal and Met*’ [23]. Potential sites of N-linked 
glycosylation are found in the amino-terminal extracel- 
lular domain at positions 47, 59, and 116, the putative 
2nd extracellular loop (position 299), and 3rd intracellu- 
lar loop (position 342). Potential sites for phosphoryla- 
tion by protein kinase C are found at positions Ser365 
and Thr375 of the 3rd intracellular loop. 
Interestingly, the full-length clone (RPR7/9.1) was 
found to contain an additional 84 bp exon in the coding 
sequence when compared to RPR7 (Fig. 4B). This inser- 
tion, encoding a further 28 amino acids (including both 
sites for potential phosphorylation), occurs in the puta- 
tive 3rd intracellular loop of the receptor polypeptide. 
Analysis of another clone (RPR7/9.8), which appeared 
to be derived from the cDNA of a partially processed 
transcript, indicated that the 5’ end of this insertion, at 
position 1,436, formed an almost perfect splice donor 
consensus equence (data not shown); the 3’ end of this 
clone occurred within the ensuing intron. Preliminary 
PCR analysis of rat pituitary RNA indicated that the 
shorter form of the transcript was predominant, sug- 
gesting that these alternate forms of the receptor are the 
result of tissue-specific differential splicing. 
3.2. Expression of RPR719.1 in transfected COS cells 
In order to determine the pharmacological character- 
istics of the novel receptor, the RPR7/9.1 cDNA was 
cloned into the mammalian cell expression vector 
pcDNA-1 (Invitrogen), and transiently transfected into 
28s - 
18s - 
Fig. 2. Northern blot analysis of receptor mRNA in rat tissues. 20 pug 
of total RNA from the indicated tissues were probed with the cDNA 
clone, RPR7. A single transcript of approximately 9.5 kb is observed 
in each lane. The positions of the 28 S and 18 S ribosomal RNAs are 
indicated. 
COS-7 cells. Since all members of the secretin receptor 
family so far identified are associated with activation of 
adenylyl cyclase, the transfected cells were stimulated 
with several potential ligands, and intracellular CAMP 
levels measured by radioimmunoassay. While treatment 
with GHRH, CRF, ACTH, CGRP and glucagon exhib- 
ited negligible effects (Fig. 5A), treatment with VIP, 
PHI and PACAP- resulted in a marked elevation of 
CAMP levels, with the latter showing the highest level 
of stimulation. PHI, VIP and PACAP- failed to stim- 
ulate CAMP levels in a control experiment where COS-7 
cells had been transfected with the 5HT,, receptor (data 
not shown). The stimulation of CAMP levels by PHI, 
VIP and PACAP was dose-dependent (Fig. 5B). The 
ECso for CAMP accumulation was approximately 0.5 
nM for PACAP-38,0.8 nM for PACAP-27, and 48 nM 
for VIP. While the ECsO for PHI was not determined, 
Fig. 5B indicates that it was very much higher than 
that of VIP. We therefore conclude that the order of 
potency of these ligands is PACAP- u PACAP- 
27 > VIP > PHI, and that accordingly, RPR7/9.1 en- 
codes a Type I PACAP receptor. 
4. DISCUSSION 
We report the cloning of a rat PACAP receptor from 
a rat olfactory bulb cDNA library. Evidence that the 
full-length clone (RPR719.1) we isolated encodes a 
PACAP receptor are: (i) the encoded protein includes 
many of the features expected of a G protein coupled 
receptor; (ii) it is highly homologous to receptors for 
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A 
CGGCACGAGCGCCTCTCCCGCAGACATAGCGGCCAA 36 
GCAGCACGGGGTGGGCGACACAGGACGAGGGGCGCCTCGCCTCGC~CGATTCCCGGC~CGACTGGCGGAGGCTCTGGAGC~CGTCCC~TG~C~TACGCACCAGCCGC~CA~GACAC 155 
AGACCCGACTGCCCGCGGCCACACGCACCGAGAGACCAGGCTC~CGCGffiCTCCGCACACGCTCCA~CGGTGCGGCTC~GCCGGATTCGCGGGTTGC~GCCCTCCTGCACATTC 274 
AGTCCCGGCGCCCAGCAGTCTGGACCGGCCCCGGAGACCAGCAGCGAG~ACAGTGGCAGGCGGCGAC~AATCTCC~GTCT~~AC~TAGCCAGAGATAG~~~CGACC 393 
ATG GCC AGA GTC CTG CAG CTC TCC CTG ACT GCT CTC CTG CTG CCT GTG GCT ATT GCT An: CAC TCT GAC TGC ATC 'I-X AAG AAG GAG CAA 483 
Met Ala Arg Val Leu Gin Leu Ser Leu Thr Ala Leu Leu Leu Pro Val Ala Ile Ala Met His Ser Asp Cys Ile Phe Lys Lys G?.u Gln 35 
GCC ATG TGC CTG GAG AGG ATC CAG AGG GCC AAC GAC CTG ATG GGA CTA AAC GAG TCT TCC CCA GGT TGC CCT GGC ATG TGG GAC AAT ATC 573 
Ala Met Cys Leu Glu Arg Ile Gin Arg Ala Asn Asp Leu Met Gly Leu Asn Glu Ser Sex- Pro Gly Cys Pro Gly Met Trp Asp Asn Xle 60 
ACA TGT TGG AAG CCA GCT CAA GTA GGT GAG AT0 FTC CTT GTA AGC TGC CCT GAG GTC 'WC CGG ATC TTC AAC CCG GAC CAA GTC TGG ATG 663 
Thr Cys Trp Lys Pro Ala Gin Val Gly Glu Met Val Leu Val Ser Cys Pro Glu Val Phe Arg Ile Phe Asn Pro Asp Gin Val Trp Met 90 
ACA GAA ACC ATA GGA GAT TCT GGT TTT GCC GAT AGT AAT TCC TTG GAG ATC ACA GAC ATG GGG GTC GTG GGC CGG AAC TGC ACA GAG GAC 753 
Thr Glu Thr Ile Gly Asp Ser Gly Phe Ala Asp Ser Asn Ser Leu Glu Ile Thr Asp Met Gly Val Val Gly Arg Asn Cys Thr Glu Asp 120 
GGC Too TCG GAG CCC TTC CCC CAC TAC TTC GAT GCT TGT GGG TTT GAT GAT TAT GAG CCT GAG TCT GGA GAT CAG GAT TAT TAC TAC CTG 843 
Gly Trp Ser Glu Pro Phe Pro His Tyr Phe Asp Ala Cys Gly Phe Asp Asp Tyr Glu Pro Glu Ser Gly Asp Gln Asp Tyr Tyr Tyr Leu 150 
TCG GTG AAG GCT CTC TAC ACA GTC 'XC TAC AGC ACT TCC CTC GCC ACC CTC ACT ACT GCC ATG GTC ATC TTG TGC CGC TTC CGG RAG CTG 933 
Ser Val Lys Ala Leu 'Iyr Thr Val Gly Tyr Ser Thr Ser Leu Ala Thr Leu Thr Thr Ala Met Val Ile Leu Cys Arg Phe Arg Lys Leu 180 
CAT TGC ACT CGC AAC TTC ATC CAC ATG AAC CTG TTT GTA TX TTC An; CTG AGG GCT ATC TCC GTC TTC ATC AAG GAC TGG AX TTG TAC 1023 
His Cys Thr Ax-g Am Phe Ile His Met Am Leu Phe Val Ser Phe Net Leu Arg Ala Ile Ser Val Phe Ile Lys Asp Trp Ile Leu Tyr 210 
GCC GAG CAG GAC AGC AGT CAC TGC TTC GTT TCC ACC GTG GAG TGC AAA GCT GTC AW GTT TTC TTC CAC TAC TGT GTG GTG TCC AAC TAC 1113 
Ala Glu Gln Asp Ser Ser His Cys Phe Val Ser Thr Val Glu Cys LYS Ala Val Met Val Phe Phe HIS Tyr fys Val Val SW Am Tyr 240 
T-PC TGG CTG TTC ATT GAA GGC CTG TAC CTC TTT ACA CTG CTG GTG GAG ACC TTC TX CCT GAG AGG AGA TAT TTC TAC TGG TAC ACC ATC 1203 
Phe Trp Leu Phe Ile Glu Gly Leu Tyr Leu Phe Thr Leu Leu Val Glu Thr Phe Phe Pro Glu Arg Arg Tyr Phe Tyr Trp Tyr Thr Ile 270 
ATC GGC TGG GGG ACA CCT ACT GTG TGT GTA ACA GTG TGG GCT GTG CTG AGG CTC TAT TTT GAT GAT GCA GGA n;C TGG GAT ATG AAT GAC 1293 
Ile Gly Trp Gly Thr Pro Thr Val Cys Val Thr Val Trp Ala Val Leu Arg Leu Tyr Phe Asp Asp Ala Gly Cys Trp Asp Met Am Asp 300 
AGC ACA GCT CTG TGG TGG GTG ATC AAA GGC CCC GTG GTT GGC TCT ATA ATG GTT AAC TTT On; CTT TTC ATC GGC ATC ATC ATC ATC CTT 1383 
Ser Thr Ala Leu Trp Trp Val Ile Lys Gly Pro Val Val Gly Ser Ile Met Val Am Phe Val Leu Phe Ile Gly Ile Ile Ile Ile Leu 330 
GTA CAG AAG CTG CAG TCC CCA GAC ATG GGA GGC AAC GAG TCC AGC ATC TAC TTC AGC TGC GlE CAG AAA TGC TAC TGC AA0 CCA CAG CGG 1473 
val Gln Lys Leu Gin Ser Pro Asp Met Gly Gly Asn Glu Ser Ser Ile Tyr Phe Ser Cys Val Gln Lys Cys Tyr Cys Lys Pro Gln Arg 360 
GCT CAG CAG CAC TCT TGC AAG ATG TCA GAA CTA WC ACC ATT ACT CTA CGG CTG GCC CGC TCC ACC CTA CTG CTC ATC CCA WC TTC GGA 1563 
Ala Gln Gln His Ser Cys Lys Met Ser Glu Leu Ser Thr Ile Thr Leu Arg Leu Ala Arg Ser Thr Leu Leu Leu Ile Pro Leu Phe Gly 390 
ATC CAC TAC RCA GTA TTC GCC TTC TCT CCA GAG AX! GTC AGC AAG AGG GAA AGA CTT GTG TTT GAG CTT GGG C'IG GGC TCC TTC CAG GGC 1653 
Ile His Tyr Thr Val Phe Ala Phe Ser Pro Glu Am Val Ser Lys Arg Glu Arg Leu Val Phe Glu Leu Gly Leu Gly Ser Phe Gin Gly 420 
TIT GTG GTG GCT GTA CTC TAC TGC TTC TTG AAT GGG GAG GTA CAG GCA GAG ATT AAG AGG AAA TGG AGG AGC TGG AAG GTG AAC CGT TAC 1743 
Phe Val Val Ala Val Leu Tyr Cys Phe Leu Asn Gly Glu Val Gin Ala Glu Ile Lys Arg Lys Trp Arg Ser Trp Lys Val Asn Arg Tyr 450 
TTC ACT ATG GAC TTC AAG CAC CGG CAC CCG TCC CTG GCC AGC AGT GGA GTA AAT GGG GGA ACC CAG CTG TCC ATC Cl% AGC AAG AGC AGC 1833 
Phe Thr Met Asp Phe Lys His Arg His Pro Ser Leu Ala Ser Ser Gly Val Am Gly Gly Thr Gln Leu Ser Ile Leu Ser Lya SW Ser 480 
TCC CAG CTC CGC ATG TCC AGC CTC CCG GCC GAC AAC TTG GCC ACC TGAOGCCTGTCTCCCTCCTCCTTCTGCACACAGGCTGG~CTGC~GCCAGTGCC~AGCA 1937 
Ser Gln Leu Arg Met Ser Ser Leu Pro Ala Asp Asn Leu Ala Thr 495 
TGTTTGTGCCTCTCCCCTCTCCTn;GGCAGDCCC~~TA~~GCTGGGCTCCTCCCC~G~AAGAGAGAGATAG~TATAGGCTGATATTGCTCCTCCTGTTT~GTCCCACCT 2056 
B 
102 
Volume 329, number 1.2 FEBSLETI’ERS August 1993 
B PheSerCysValGlnLysCysTyrCysLysProGlnArgAlaGlnGlnHisSerCysLysMetSerGluLeuSerThrIleThrLeu CAGCTGCGTGCAGAAATGCTACTGCAAGCCACAGCCACAGCGGGCTCAGCAGCAC~~GC~GATGTCAGAACTATCCACCA~ACTCT 
- 
SerIleTyr 1 ArgLeuAla 
AGCATCTACTTACGGCTGGCC 
SerIleTyrLeuArgLeuAla 
Fig. 4. (A) Alignment of the rat PACAP, VIP, secretin, GHRH, GLP, glucagon, PTH and calcitonin receptors. Amino acids identical in all eight 
receptors are indicated with an asterisk. Putative transmembrane r gions are indicated by lines above the sequence. (B) Generation of isoforms 
of the rat PACAP receptor by differential RNA processing. The top line indicates the nucleotide sequence and translation of RPR7j9.1 between 
positions 1,436 and 1,521. This 84 base insertion is spliced out to give rise to the shorter isoform of the receptor shown below. 
other secretin-like peptides which include PACAP; (iii) 
expression of the cDNA in transfected COS cells results 
in PACAP-stimulated production of CAMP. 
Most sequence identity between the PACAP receptor 
and other members of the receptor family occurs in the 
putative transmembrane domains. The N-terminal do- 
mains, while highly divergent, exhibit substantial ho- 
mology at specific amino acid positions. These include 
6 cysteine residues which have been postulated to confer 
a general structure to the extracellular ligand binding 
domains of these receptors [lo]. The PACAP receptor 
exhibits the highest degree of homology with the VIP 
receptor (Sl%), which reflects the high sequence identity 
of their respective ligands (68%). 
While many genes encoding G protein-coupled recep- 
tors lack introns, there is increasing evidence that mem- 
bers of the secretin receptor family are large and inter- 
rupted by numerous introns. For instance, Mayo [lo] 
identified two isoforms of the rat GHRH receptor 
which differed by the presence of a 124 base xon in the 
region encoding the putative third intracellular loop. 
Similarly, we have identified two isoforms of the 
t 
Fig. 3. Sequence of the rat PACAP receptor cDNA and polypeptide. (A) DNA sequence and predicted amino acid sequence of rat cDNA clone 
RPR7/9.1. (B) Hydropathy plot of the rat PACAP receptor protein. The strongly hydrophobic region at the N-terminus corresponds to the signal 
sequence. A further seven hydrophobic putative membrane spanning regions are numbered from 1 to 7. The numbers on the horizontal scale refer 
to amino acid positions. 
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Fig. 5. Stimulation of CAMP production in COS cells transfected with RPR7/9.1. (A) Stimulation of CAMP production by various ligands. Cells 
transfected with RPR7/9.1 were stimulated with the ligands indicated, each at a concentration of 100 nM. Values of CAMP are expressed as the 
mean+S.E.M. (n = 3). (B) Dose-response curves of CAMP stimulation in COS cells stimulated by PACAP (0) PACAP (Q, VIP, (0) and PHI 
(r). The values represent he mean f S.E.M. (n = 4). Basal CAMP level was 0.42 + 0.06 pmoUwel1. 
PACAP receptor which differ by the presence or ab- 
sence of an 84 base exon in an identical location. Anal- 
ysis of other clones which appeared to be derived from 
cDNAs of unprocessed RNAs revealed the presence of 
other introns within the coding sequence (J.A. Morrow 
and KM. West, unpublished data). This is analogous 
to the D2 receptor where alternative splicing gives rise 
to two isoforms, one with a 29 amino acid insert in the 
third intracellular loop [24-261. The longer form was 
found to predominate in the pituitary. Since the third 
intracellular loop is associated with the interaction with 
G proteins, it is possible that the longer and shorter 
isoforms of these proteins differentially interact with G 
proteins to activate different second messenger path- 
ways. 
Receptor binding studies have provided evidence for 
the presence in tissues of four types of membrane recep- 
tor capable of specific binding of PACAP The Type II 
receptor [27] recognises VIP, PACAP- and PACAP- 
38 with very similar affinities, and may correspond to 
the cloned VIP receptor [3,4]. This receptor is present 
in a variety of peripheral tissues, including rat liver, rat 
lung, mouse splenocytes and human small intestinal ep- 
ithelium 127-311. The human lymphoblastic cell line, 
SUP-Tl, contains a receptor which binds VIP and 
PACAP but for which helodermin is the most potent 
ligand [32]. Type I receptors which are highly specific 
for PACAP, but bind VIP with only modest aITmity 
[27]) have been described in brain and pituitary 
[28,33,34], rat astrocytes in culture [35], testis [27] and 
adrenal medulla [27]. A variety of cell lines, including 
NB-OK neuroblastoma cells [36], PC12 phaeochro- 
mocytoma cells [37], the rat pancreatic acinar cell line 
AR 4-25 [38] and the THP-1 monocytic leukaemia cell 
line [39] have also been shown to possess Type I PACAP 
receptors. 
Studies of PACAP binding to membranes from the 
104 
rat central nervous system [33] and from the rat pancre- 
atic tumour cell line AR4-2J [40,41] have led to the 
division of Type I PACAP receptors into two subclasses 
(PACAP-IA and PACAP-IB). PACAP-IA receptors 
bind PACAP- with slightly higher affinity than 
PACAP-38, whereas PACAP-IB receptors recognise 
PACAP- with high affiity and PACAP- with low 
affinity. PACAP-38-preferring receptors have also been 
described in hypothalamus [42] and pituitary [28]. 
Our data, which demonstrate that RPR7/9.1 encodes 
a receptor with high affinity for PACAP (ECsO = 0.5 
nM for PACAP and 0.8 nM for PACAP27) and re- 
sponds to ligands with the order of potency PACAP 
- PACAP > VIP > PHI, is consistent with RPR719.1 
being a Type I receptor. It has yet to be established 
unambiguously, however, whether it is Type IA or IB. 
While PACAP activates adenylyl cyclase and in- 
creases CAMP levels in various tissues, it has also been 
shown to stimulate the phosphatidyl inositol cascade 
and mobilise intracellular Ca2+ [43-45]. It will be inter- 
esting to determine if RPR719.1 can also stimulate the 
Ca2’/inositol phosphate pathway, and whether the two 
receptor isoforms we have described differ in their abil- 
ity to activate these intracellular effector systems. 
The ~haracte~sation of the PACAP receptor will be 
of considerable importance for our understanding of 
the physiology of PACAP and may facilitate the devel- 
opment of specific PACAP agonists and antagonists. 
The presence of PACAP receptors in the central nerv- 
ous system suggests that PACAP may play a role in the 
pathogenesis of psychiatric, neurological and neuroen- 
docrine disorders. Type I PACAP binding sites have 
been described in the adrenal medulla [27], and PACAP 
has been implicated in the regulation of adrenal chro- 
maffin cells, perhaps in the synthesis and secretion of 
catecholamines [46]. Type I receptors have also been 
described in pancreatic acinar cells [40] where PACAP 
Volume 329, number 1,2 FEBSLETTERS August 1993 
has been suggested to regulate pancreatic exocrine ac- 
tivity [47]. The presence of Type I receptors in the sper- 
matozoa and other sites of the reproductive system [27] 
suggests that PACAP may play an important role in 
disorders and control,of fertility. Finally, the presence 
of PACAP receptors in various tumour cell lines [36 
401, and lung cancer cells [48] suggests he possibility of 
alterations in PACAP signal transduction being in- 
volved in oncogenesis. 
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